- Ixchiq chikungunya vaccine has caused seventeen serious adverse events, including two deaths, in adults aged 62 to 89.
- FDA and CDC recommend a pause in the use of Ixchiq in patients aged 60 years and older.
- An updated benefit-risk assessment is underway to evaluate the safety of Ixchiq in older patients.
- Ixchiq’s prescribing information includes a warning regarding potential severe or prolonged adverse reactions.
- Severity of adverse events prompted FDA and CDC guidance to pause Ixchiq use in older adults.
Source: FDA
